Speaker
Edward Stites, MD, PhD, Salk Institute for Biological Studies
At the conclusion of this activity, learners should be able to:
* Describe clinical trial data showing variation in how RAS mutant cancers respond to treatment
* Describe ongoing studies subclassifying RAS mutants into those that are biomarkers for EGFR inhibitor sensitivity and for EGFR inhibitor resistance
* Identify computational simulations as an emerging computational tool for studying pathogenic mutations and their response to treatment
Event Series
Pathology Grand Rounds